1 |
Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-2165.
DOI
ScienceOn
|
2 |
Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009;11:94-101.
DOI
ScienceOn
|
3 |
Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-542.
DOI
ScienceOn
|
4 |
Pawlowski R, Mühl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2013;132:E11-E17.
DOI
ScienceOn
|
5 |
Lambert SR, Harwood CA, Purdie KJ, Gulati A, Matin RN, Romanowska M, et al. Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene. Int J Cancer 2012;131: E216-E226.
DOI
ScienceOn
|
6 |
Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-158.
DOI
ScienceOn
|
7 |
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-607.
DOI
ScienceOn
|
8 |
Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, et al. Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer 2012;131:2456-2464.
DOI
ScienceOn
|
9 |
Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, et al. Molecular target class is predictive of in vitro response profile. Cancer Res 2010;70:3677-3686.
DOI
|
10 |
McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007;104: 19936-19941.
DOI
ScienceOn
|
11 |
Kim N, Park H, He N, Lee HY, Yoon S. QCanvas: an advanced tool for data clustering and visualization of genomics data. Genomics Inform 2012;10:263-265.
DOI
ScienceOn
|
12 |
Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011; 39:D945-D950.
DOI
|
13 |
Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003;100:776-781.
DOI
ScienceOn
|
14 |
Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis 2000;21:379-385.
DOI
ScienceOn
|
15 |
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499: 214-218.
DOI
ScienceOn
|
16 |
Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
|
17 |
Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191-196.
DOI
ScienceOn
|